Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Other(2)

Detailed Status

Completed2

Suspended2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

completed250%

suspended250%

Recent Activity

0 active trials

Showing 4 of 4

suspendedphase_1

Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation

NCT01841463

suspendedphase_1

Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

NCT02117336

completedphase_1

A Multicenter Phase I Clinical Study of a New Compound P1446A-05 in Patients With Advanced Refractory Malignancies

NCT00772876

completedphase_1

A Study Of Selective Cyclin Dependent Kinase Inhibitor P1446A-05 In Subjects With Advanced Refractory Malignancies

NCT00840190

Clinical Trials (4)

Showing 4 of 4 trials

NCT01841463Phase 1

Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation

Suspended

NCT02117336Phase 1

Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Suspended

NCT00772876Phase 1

A Multicenter Phase I Clinical Study of a New Compound P1446A-05 in Patients With Advanced Refractory Malignancies

Completed

NCT00840190Phase 1

A Study Of Selective Cyclin Dependent Kinase Inhibitor P1446A-05 In Subjects With Advanced Refractory Malignancies

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4